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Edited by Veli-Pekka LehtoAbstract Dendritic cells (DC) are known to not only induce the
activation of T cells, but are also associated with the polarization
of T cells. This study investigated whether or not proteoglycan
(PG) isolated from Phellinus linteus induces the phenotypic and
functional maturation of CD11cþ DC in vitro and in vivo. PG
was found to induce the phenotypic and functional maturation of
bone marrow-derived DC via Toll-like receptors (TLR) 2 and 4
in vitro. Administration of PG in vivo strongly inhibited the
MCA-102 tumor growth and increase in vivo. The ratio of CD8þ
DC to CD8 DC increased, and PG enhanced IL-12 and IFN-c
production, and expression of surface molecules including major
histocompatibility complexes (MHC) classes I, MHC II, CD80,
and CD86 in MCA-102-challenged mice. PG also caused a
marked increase in the production of Th (helper T cells)-1
cytokine (IFN-c) and a decrease in the production of Th-2
cytokine (IL-4) by splenic cells and inguinal lymph node cells in
MCA-102 tumor-bearing mice. Furthermore, PG stimulated the
proliferation of CD4þ and CD8þ T cells. In addition, a
combination of PG and tumor lysate-pulsed DC inhibited
completely the growth of MCA-102 cells in tumor-bearing mice.
These results indicate that the administration of PG inhibited the
tumor growth through a mechanism leading to a Th-1 dominant
immune state and the activation of CD11cþCD8þ DC.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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There is much attention currently focused on the use of
dendritic cells (DC) in immuno-cell therapy against hemato-
poietic and solid tumors. DC are professional antigen-* Corresponding author. Fax: +82-51-243-2259.
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doi:10.1016/j.febslet.2004.09.047presenting cells (APC) with a unique and potent capacity to
induce innate and adaptive immune responses [1] as well as an
ability to regulate the T cell-mediated immune responses [2,3].
DC can also prime naive T cells to antigens and dictate the
development of T cell-mediated immune responses into either
the helper T cells (Th)-1 or Th-2 type [4]. Activation of the
CD4þ Th-1 cells that produces primarily interleukin-2 (IL-2)
and interferon-c (IFN-c) is necessary in order to induce cel-
lular immunity in mice. The Th-2 cells that produce IL-4, IL-5,
IL-10 and IL-13 control humoral immunity [5,6]. The devel-
opment of Th-1 or Th-2 types from naive cells to eﬀector cells
is regulated by the presence of speciﬁc cytokines in the mi-
croenvironment at the time of T cell priming. For Th-1 cells,
IL-12 is an essential cytokine of diﬀerentiation, whereas for
Th-2 cells, IL-4 and IL-10 are critical [7,8]. In mice, the CD8þ
DC, but not the CD8 DC subset, has the capacity to produce
a large amount of IL-12, which is the most important cytokine
in the induction of Th-1 cells [9].
A variety of biological response modiﬁers that modulate the
host biological responses against tumors have been developed
as adjuvants for applications in cancer therapy. Such agents
have been capable of potentiating the host immune responses
without direct cytotoxicity to cancer cells [10]. In a compara-
tive study of anti-tumor activities by polysaccharides from
basidiomycetes, a more than 80% growth inhibition of Sar-
coma 180 transplanted into immunocompetent ICR mice was
observed [11]. Most notably, the hot water-crude extract of
Phellinus linteus was the most potent, the growth-inhibiting
properties of which were signiﬁcantly apparent in that system
[12]. It has been reported that the polysaccharides puriﬁed
from the mycelial culture of P. linteus stimulate both the
proliferation of T lymphocytes and the humoral immune
function via the polyclonal activation of B cells [13,14]. It has
also been shown that the culture ﬁltrate of Phellinus sp. con-
tains cyclophellitol. This compound suppresses the metastatic
potential of tumor cells by interfering with the synthesis of the
cell surface carbohydrates [15,16].
We previously reported that proteoglycan (PG) isolated from
P. linteus enhanced the proliferation of splenic lymphocytes
[17]. PG increased the proliferation of B lymphocytes viaation of European Biochemical Societies.
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T lymphocytes [18]. PG also induced the phenotypic and
functional maturation of bone marrow-derived DC through
increased surface molecules, IL-12p70, mixed lymphocyte re-
actions, and migration into the lymphoid organs [19]. However,
the reciprocal relationship between DC and PG in tumor-
bearing mice is unknown. Therefore, this study investigated the
roles of splenic and draining lymph node DC in MCA-102
tumor-bearing mice administered with PG. The study also in-
vestigated whether or not the administration of PG has an eﬀect
on tumor rejection through the activation of CD4þ Th cells and
cytotoxic CD8þ T cells. Notably, regarding anti-tumor activi-
ties, these immunostimulating activities of PG might be related
to the maturation of CD11cþCD8þ DC in lymphoid organs.2. Materials and methods
2.1. Animals
Female C57BL/6 mice (6–8 weeks old) were obtained from the
Korean Institute of Chemistry Technology (Daejeon, Korea). They
were maintained under pathogen-free conditions until used. Sterilized
food and water were supplied ad libitum, and the mice were housed
under a 12-h day/night cycle.
2.2. Preparation of PG
PG was isolated from the mushroom P. linteus by using ethanol
precipitation methods followed by DEAE-cellulose and gel ﬁltration
chromatography [17]. The molecular weight of PG was estimated to be
approximately 150 kDa. It contained 72.2% polysaccharide and 22.3%
protein. It was determined to be an acidic proteoheteroglycan. The
main components of PG are polysaccharides that consist of mannose
(41.6%), glucose (23.4%) and galactose (23.8%). Analysis by gas
chromatography showed that PG was free of lipids. Endotoxin was
assayed under endotoxin-free experimental conditions by using a
Limulus Amebocyte Lysate (LAL) Pyrogen Kit (Biowhittaker, Walk-
ersville, MD). The experiments were conducted according to the
manufacturer’s protocol: 100 ll of standards, PG or controls was
mixed with 100 ll of the LAL reagent and incubated for 1 h at 37 C.
Each tube was then examined for gelation. The quantity of endotoxin
in PG was 6 0.01 ng/mg.
2.3. Administration of PG and tumor growth analysis
MCA-102 tumor cells (1 106) were implanted in the right ﬂank of
female C57BL/6 mice (6–8 weeks old). Next, PG (100 mg/kg/day) or
saline (control) was administered to the tumor-bearing mice intraper-
itoneally (i.p.) for 19 consecutive days. On day 20, in PG- or PBS-
administered mice, the spleens or the inguinal lymph nodes (iLN) were
removed and dissociated with collagenase in Ca2þ-free media in the
presence of EDTA. They were separated into low- and high-density
fractions on a Nycodenz gradient.
2.4. Assessment of cell viability
Cell viability was assessed using methyl thiazolyl tetrazolium (MTT)
staining. 100 ll of cell culture containing 1 104 cells was plated in
the wells of 96-well culture plates. After incubation with PG for 48 h,
100 ll of MTT solution (2.5 mg/ml) was added. After incubation at
37 C for 4 h, 100 ll of acid-isopropanol (0.04 N HCl in isopropanol)
was added and mixed gently with the cell suspension and OD560 was
determined with ELISA reader.
2.5. Flow cytometric analysis
Whole spleen cells or lymph node cells were ﬁrst blocked with 10%
(v/v) normal goat serum for 15 min at 4 C and stained with PerCP-
conjugated anti-CD8 (clone: 53-6.7), PE-conjugated anti-H2Kb (AF6-
88.5), anti-IAb (AF6-120.1), anti-CD80 (16-10A1), and anti-CD86
(GL1) with ﬂuorescein isothiocyanate (FITC)-conjugated anti-CD11c
(HL3) antibody (PharMingen, SanDiego, CA) for 30 min at 4 C. In
parallel experiments, the cells were stained with PerCP-conjugated
anti-CD3 (145-2C11), phycoerythrin (PE)-conjugated anti-CD8 (53-
6.7), and FITC conjugated anti-CD4 (GK1.5) antibody (PharMingen).The stained cells were analyzed using a FACSCalibur (Becton Dick-
inson, San Jose, CA) with the CellQuest program.
2.6. Intracellular cytokine staining
Cells were ﬁrst blocked with 10% v/v normal goat serum for 15 min at
4 C and then stained with FITC-conjugated anti-CD11c antibody for
30min at 4 C. The cells stainedwith the appropriate isotype-matched Ig
were used as the negative controls. The cells were ﬁxed and permeated
with the Cytoﬁx/Cytoperm kit (PharMingen), according to the manu-
facturer’s instructions. For intracellular IL-12 p40/p70 and IFN-c de-
tection in CD11cþ DC, DCwere stained with PE-conjugated antibodies
(PharMingen) in a permeation buﬀer. In a parallel experiment, for in-
tracellular IL-4 and IFN-c detection in CD3þ T cells, they were stained
with PE-conjugated anti-IL-4 and FITC-conjugated anti-IFN-c with
PerCP conjugated anti-CD3 antibodies (PharMingen). The cells were
analyzed using a FACSCalibur.
2.7. Generation of bone marrow (BM)-derived myeloid DC and tumor
growth
Bone marrow cells were collected from the marrow of femurs and
tibiae of mice under aseptic conditions. The BM cells were cultured in
a culture medium (Opti-MEM, 2 mM L-glutamine, 10% fetal bovine
serum, 50 lMmercaptoethanol and 100 U/ml penicillin) supplemented
with 20 ng/ml recombinant murine (rm) GM-CSF and 20 ng/ml rmIL-
4 at 1 106 cells/ml. The DC were harvested from 4-day culture, wa-
shed, and resuspended at 5 106 cells/ml. The DC populations were
enriched by 14.5% metrizamide. Viable MCA-102 tumor cells were
suspended at 1 107 cells/ml. The tumor cell lysates were generated by
ﬁve rapid freeze-thaw cycles as described in [20]. The tumor cell lysates
were collected and incubated overnight with puriﬁed DC at a tumor-
cell-to-DC ratio of 3:1. The tumor cell lysates-pulsed DC (TP-DC) or
unpulsed DC (Normal-DC) (1 106 cells) were introduced subcuta-
neously into C57BL/6 mice. One week later, 1 106 MCA-102 tumor
cells were intradermally (i.d.) inoculated into the left ﬂank of the mice.
One group of TP-DC mice was treated with PG for 19 consecutive
days starting from that day. In order to determine whether PG has a
direct eﬀect on the MCA-102 introduced tumors, C57BL/6 mice were
i.d. implanted with 1 106 MCA-102 tumor cells per mouse on day 0.
After 24 h, saline or PG (100 mg/kg/day) was administered to the tu-
mor-bearing mice i.p. for 19 consecutive days. The sizes of the tumors
were determined every 7 days using the microcaliper: tumor volume
(mm3) ¼ (major axis) (minor axis)2 0.5236 [21].
2.8. Statistical analysis
The results were expressed as means SD of the indicated number
of experiments. The statistical signiﬁcance was estimated using a Stu-
dent’s t test for unpaired observations. A P value of <0.05 was con-
sidered to be signiﬁcant.3. Results
3.1. Administration of PG in vivo inhibits growth of MCA-102
tumor cells
The eﬀects of PG on tumor growth in mice implanted with
MCA-102 tumor cells are shown in Fig. 1A. The MCA-102
cells were implanted in the mice on day 0. Saline (control) or
PG 100 mg/kg/day was administered intraperitoneally for 19
consecutive days. PG signiﬁcantly delayed tumor growth
(Fig. 1A) and suppressed tumor weight (Fig. 1B). Tumor
formation was somewhat inhibited in all mice administered
with PG. The ﬁnal tumor weight on day 20 was reduced by
about 41% by the PG treatment. These results suggest that the
administration of PG may enhance anti-tumor capacity
through immune-modulatory activity, because PG is not di-
rectly cytotoxic to MCA-102 cells (Fig. 1C). Also, the ad-
ministration of PG did not show any apparent side eﬀects such
as a decrease of body weight (Fig. 1D). These results clearly
indicate that PG was eﬀective in preventing the experimental
tumor growth of MCA-102 cells.
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Fig. 1. Administration of in vivo PG inhibits the growth and increase of MCA-102 tumor cells. Mice were subcutaneously implanted with MCA-102
cells on day 0. PG was intraperitoneally administered at 100 mg/kg/day for 19 consecutive days (open circle). The mice of the control group were
given saline (closed circle). Tumor size was measured from day 7 (A). The tumors were excised and weighed on day 20 (B). Assessment of cytotoxicity
in PG-treated MCA-102 cells was incubated with various concentrations of PG (C). The body weight of mice was measured (D). The number of mice
per group was ﬁve (n ¼ 5). The signiﬁcance was determined by Student’s t test (*, P < 0:05).
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BM-DC via Toll-like receptors (TLR) 2 and 4
To evaluate whether PG inﬂuences the phenotypic matura-
tion of DC, BM-derived immature DC from day-6 murine bone
marrow cultures were cultured with PG or LPS (positive con-
trol) for 24 h and then analyzed for any surface expression of
MHC class II or costimulatory molecule, CD86. LPS was in-
cluded in these experiments as a positive control for DC mat-
uration. An analysis of the cell surface markers demonstrated
that most cells expressed CD11c (84%), but not CD3 or CD19
(data not shown). Fig. 2A (thick lines) shows that PG, similarly
to LPS, induced a dramatic upregulation of MHC II and co-
stimulatory molecule, CD86, on the surface of CD11cþ DC.
The upregulation of these molecules was already observed after
6 h of stimulation and was not due to LPS contaminating the
PG preparation, since PG did not show any eﬀect in the pres-
ence of polymyxin B (PB), an LPS inhibitor (thin line). PB ef-
fectively inhibited the membrane expression of MHC II and
costimulatory molecules, CD86, increased by LPS, but had no
eﬀect on the untreated- and PG-treated DC. Also, we analyzed
the intracellular IL-12 p40/p70 production by PG-treated DC.
As shown in Fig. 2B, intracellular staining of FITC-conjugated
CD11cþ DC with PE-conjugated IL-12 p40/p70 mAbs revealed
that PG- or LPS-treated DC signiﬁcantly enhanced IL-12 p40/
p70 production compared to the control DC. Also, theincreasing eﬀect of PG treated DC on IL-12 p40/p70 expression
was independent of LPS contamination because PB was
strongly blocking IL-12 p40/p70 production in LPS-stimulated
DC, but not in PG-treated DC. Additionally, to assess whether
PG-induced maturation of DC is initiated through TLRs 2 and
4, we examined the eﬀects of anti-TLR2 and anti-TLR4 Ab
treatment on the PG-induced phenotypic maturation of DC to
further characterize the membrane receptors of PG. As shown
in Fig. 3, anti-TLR2 and anti-TLR4 signiﬁcantly decrease the
PG-induced CD86 andMHC class II expression, and IL12 p40/
p70 production. Thus, these observations indicate that PG in-
creases the costimulatory molecule CD86 and theMHC class II
molecule, and that IL-12 production in DC in vitro and PG-
induced phenotypic maturation of DC are possibly mediated
by TLR 2 and 4.
3.3. PG administration induces phenotypic maturation of
CD11cþCD8þ DC in lymphoid organs
To determine whether or not the administration of PG in-
duces the phenotypic maturation of the CD11cþ DC in tumor-
bearing mice, the study investigated the costimulatory and
MHC molecules of the CD11cþ cells of the spleen and lymph
nodes. As shown in Fig. 4, the PG administration was suﬃ-
cient to increase the expression of CD80, CD86, MHC I, and
MHC II in CD11cþ cells in tumor-bearing mice. The mean
Fig. 2. PG enhances the expression of costimulatory and MHC class II molecules, and the intracellular IL-12 production of BM-DC. DC were
generated as described in Section 2. On day 7, the cells were harvested and analyzed by two-color ﬂow cytometry. The cells were gated on CD11cþ.
The DC were stimulated for 24 h with 100 lg/ml PG or 200 ng/ml LPS on day 6 in the absence (thick line) or presence (thin line) of the LPS inhibitor,
polymyxin B (PB) (A). Analysis of IL-12 p40/p70 expression in CD11cþ DC by intracellular cytokine staining after PG or LPS stimulation (24 h) in
the absence or presence of PB (B). The numbers indicate the percentages of CD11cþ cells expressing IL-12 p40/p70. The histograms show ﬂuo-
rescence values on gated large cells. The data are from one representative experiment out of 3 performed.
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CD11cþ cells was stronger in the lymph node cells than in the
splenic cells (Fig. 4A). The population of surface molecule-
positive cells was unchanged in the splenic cells, compared
with that in the control mice (Fig. 4B), although a strong MFI
was shown. However, the PG-treated mice signiﬁcantly in-
creased the frequency (%) of CD80þ and CD86þ in the
CD11cþ cells in the lymph nodes, compared with the control
mice (Fig. 4C). In addition, the eﬀects of PG on CD11cþ DC
subclasses were investigated by a ﬂow cytometric analysis.
CD8þ DC were reported to involve the activation and diﬀer-
entiation of Th cells by providing costimulatory signals, by
which CD8þ DC have been the development of Th-1 cells [21].
Accordingly, we investigated whether PG induces maturation
of CD8þ DC. As shown in Fig. 5, the frequency of
CD11cþCD80þCD8þ and CD11cþCD86þCD8þ cells in thesplenic and lymph node DC dramatically increased upon the
administration of PG. These results suggest that activated
CD8þ DC are involved in priming the Th-1 subset to respond
to PG for the inhibition of tumor growth.
3.4. PG administration increases the level of intracellular IL-12
and IFN-c in CD11cþ DC
Next, we investigated whether or not the administration of
PG can induce the production of cytokines such as IL-12 and
IFN-c in CD11cþ DC in tumor-bearing mice. As shown in
Fig. 6, CD11cþ DC from PG-treated mice dramatically en-
hanced the intracellular levels of IL-12 and IFN-c in the spleen
and lymph nodes. These results suggest that PG might enhance
the ability of DC to produce some cytokines and develop the
diﬀerentiation to the Th-1 cells of the CD4þ T cells in the
lymphoid tissues of tumor-bearing mice.
Fig. 3. PG induces the phenotypic and functional maturation of BM-DC via Toll-like receptors (TLR) 2 and 4 in vitro. DC were generated as
described in Section 2. On day 7, the cells were harvested and analyzed by two-color ﬂow cytometry. The cells were gated on CD11cþ. The DC were
stimulated for 24 h with 100 lg/ml PG on day 6 in the absence or presence of anti-TLR 2 or anti-TLR 4 Abs (A). Analysis of IL-12 p40/p70 ex-
pression in CD11cþ DC by intracellular cytokine staining after PG stimulation (24 h) in the absence or presence of anti-TLR 2 or anti-TLR 4 Abs
(B). The numbers indicate the percentages of CD11cþ cells expressing IL-12 p40/p70. The histograms show ﬂuorescence values on gated large cells.
The data are from one representative experiment out of 3 performed.
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vivo
Fig. 7 shows the population of CD4þ T cells in the splenic
cells and lymph node cells of C57BL/6 treated with PG. The
populations of CD3þCD4þ in the control and PG treated mice
were 12.7% and 34.2% in the spleen cells, and 24.1% and 45.8%
in the lymph node cells, respectively (Fig. 7A). The CD4þ cells
proliferated in response to PG in a concentration-dependent
manner. The CD3þCD4þ cell population for a half-dosage of
PG (50 mg/kg) increased, respectively, by 23.4% and 35.7% in
the splenic and lymph node cells (data not shown). The
CD3þCD8þ cells of the spleen and lymph nodes treated with
PG increased by 13.2% and 14.4%, respectively (Fig. 7B).These results suggest that PG increases antigen-presentation
activities in CD11cþCD8þ DC.
We also investigated whether or not PG is linked to the
CD28/B7 pathways related to T-cell activation via a non-spe-
ciﬁc signal resulting from the binding of the B7 ligand on the
APC with its receptor, CD28, on the T cells. As shown in
Fig. 4, PG increased the expression of the CD28 ligands, B7.1
and B7.2, on CD11cþ DC in the spleen and lymph nodes. To
investigate whether PG enhances the activation of DC in
priming antigen-speciﬁc Th cells and CTL in vivo, the ex-
pression of CD28 on T cells, which bind B7 costimulatory
molecules to DC, was examined by ﬂow cytometryic analysis.
PG dramatically enhanced CD4þ and CD8þ T cell subpopu-
Fig. 4. Administration of in vivo PG increases the expression of costimulatory (CD80 and CD86) and MHC (I and II) molecules on the CD11cþ DC
of the spleen and lymph nodes in tumor-bearing mice. On day 20, the cells were harvested and analyzed by two-color ﬂow cytometry. The cells were
gated on CD11cþ. The mean ﬂuorescence intensity (MFI) of the CD11cþ cells expressing Ag is indicated within each histogram (control MFI/PG-
treated MFI: (A) Unstimulated CD11cþ DC (dashed lines) were compared with PG-stimulated CD11cþ DC (thick lines). Thin lines represent
isotype controls. The populations of CD11cþ expressing the Ag are depicted in the spleen (B) and lymph node cells (C). The histogram is from one
representative experiment out of three performed. The signiﬁcance was determined by Student’s t test (*, P < 0:05). iLN, inguinal lymph nodes.
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to the level in the control mice, PG induced CD28 expression
on CD4þ T cells up to 2-fold and on CD8þ T cells up to 3-fold.
These results indicate that PG enhanced CD4þ T cell and
CD8þ T cell-generation of tumor-rejection immunity in vivo.
3.6. PG administration modulates Th-1 polarization
IL-12 has multiple immunoregulatory functions, inducing
the activation of the Th-1 subset, which plays a pivotal role in
the induction of in vivo anti-tumor immunity [20]. PG ad-
ministration increased IL-12 production on CD11cþ DC in the
spleen and lymph nodes (Fig. 6). Therefore, we attempted to
examine the production of Th-1- and Th-2-type cytokines inthe spleen and lymph node cells of tumor-bearing mice treated
with PG. The T cells of the spleen and lymph nodes of the PG-
treated mice showed a signiﬁcant enhancement of intracellular
IFN-c and a decrease in intracellular IL-4 production as
compared with those in the control mice (Fig. 8). Thus, the
ﬁndings indicate that PG administration induces the produc-
tion of IL-12 and IFN-c in CD11cþ DC in tumor-bearing
mice.
3.7. Combination therapy of PG and tumor lysate-pulsed (TP)
DC completely inhibits the growth MCA-102 cells
As shown in Fig. 9, C57BL/6mice were once administered s.c.
through 1 106 tumor lysate-pulsed DC (TP-DC) or unpulsed
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cells were i.d. inoculated into the left ﬂank. The inoculation with
normal-DC failed to decrease the tumor growth. After inocu-
lation with TP-DC in the absence or presence of PG treatment
for 19 consecutive days, tumor growth was delayed in all TP-
DC immunized groups. No tumor formation was observed in
the TP-DC + PG on day 28 of the post-tumor challenge.
Moreover, three out of ﬁve mice in the TP-DC + PG group
achieved complete rejection by day 60 after the MCA-102 tu-
mor challenge (data not shown). These results suggest that the
vaccine eﬃciency of combination therapy completely inhibited
tumor growth through the activation of CD4þ Th-1 cells and
CD8þ cytotoxic T cells. Antigen-speciﬁc DC expressing MHC
and costimulatory molecules in PG administration dramatically
induced the activation of CD4þ and CD8þ T cells.4. Discussion
Our study demonstrated that the treatment of PG signiﬁ-
cantly inhibited the growth of MCA-102 tumor cells in mice
without causing any adverse eﬀects such as weight loss, indi-
cating that PG might prevent the growth of MCA-102 tumor
cells (Fig. 1). PG administration resulted in a marked aug-
mentation of costimulatory and MHC molecules, as well as theproduction of pro-inﬂammatory cytokines, by CD11cþCD8þ
DC in tumor-bearing mice. Notably, enhanced IL-12 and IFN-
c production in CD11cþ DC resulted in an increased ability to
induce IFN-c and a decreased ability to induce IL-4 in CD4þ
T cells. These results also suggest that PL administration
strongly activates DC loaded with tumor antigen, inducing the
activation of anti-tumor protective immunity in CD4þ Th-1
cells and cytotoxic CD8þ T cells.
In a previous study, PG strongly stimulated both cell-med-
iated and humoral immunity in vivo and in vitro [13]. PG
activated most immune cell types such as natural killer cells,
macrophages, T cells, and B cells. From these results, it is clear
that PG increases the non-speciﬁc host defenses that play an
important role in eliminating tumor cells and the action pro-
ﬁles of PG might be similar to those of IL-2, one of the well
known immunotherapeutics [12,13]. PG can be recommended
as an improved candidate over immunochemotherapy with
IL-2 [12]. However, the anti-tumoral mechanisms of PG,
particularly those in the maturation of DC, have not yet been
found. Our study demonstrated that PG induced the pheno-
typic and functional maturation of BM-derived DC in vitro.
Thus, we also investigated whether or not the administration
of PG activated CD11cþ DC in tumor-bearing mice.
Fig. 7. Administration of PG in vivo induces the activation of CD4þ and CD8þ T cells in the spleen and lymph nodes of tumor-bearing mice. On day
20, the cells were harvested and analyzed by three-color ﬂow cytometry. The incidence of CD4þ (A) and CD8þ (B) T cells within the CD3þ cells in
tumor-bearing mice was analyzed. The results are representatives of three separate experiments. iLN: inguinal lymph nodes.
Table 1
Eﬀect of PG on T cell activation in tumor-bearing mice
Control-mice PG-mice
spleen (%)a iLN (%) spleen (%) iLN (%)
CD4þCD28þ 5.3 0.8 4.3 1.2 9.3 2.3b 9.8 1.1b
CD8þCD28þ 0.9 0.2 1.3 0.4 2.5 0.6b 4.4 0.8b
Data represent means SD of three diﬀerent experiments.
a% of positive cells was determined by ﬂow cytometric analysis.
b P < 0:05, compared with control-mice (Student’s t test).
398 G.-Y. Kim et al. / FEBS Letters 576 (2004) 391–400DC are potent antigen-presenting cells capable of capturing
antigens and processing and presenting antigenic peptide
fragments. Mature DC cells can migrate to lymphoid organs
and enhance to prime T cells [2,22]. Due to these properties,DC are considered to be promising in cancer immunotherapy.
Also, based on their ability to induce Th-1 versus Th-2 po-
larization, mature DC have been called DC1 or DC2, respec-
tively [23]. Myeloid DC give rise to DC1 or DC2, depending
on the nature of the maturation stimuli inﬂuencing IL-12
production [24–27]. Also, IL-12, produced by DC, macro-
phages, and other antigen-presenting cells, is known to have
potent anti-tumor activities [28,29]. IFN-c appears to be the
most potent DC-1-promoting factor and is a cytokine that
plays an important role in inducing and modulating a cascade
of immune responses [25,28,30]. Recent studies have indicated
that the ratio of Th-1 to Th-2 subsets is closely correlated with
the outcome of many diseases [31,32], and controlling this
Th-1 to Th-2 ratio has been demonstrated as a therapeutic
strategy [33]. Notably, the induction of Th-1 immune
Fig. 8. PG administration in vivo modulates Th-1 type polarization. On day 20, the cells were harvested and analyzed by three-color ﬂow cytometry.
The cells were gated on CD3þ T cells. Analysis of intracellular IL-4 and IFN-c productions in CD3þ T cells by intracellular cytokine staining in
spleen and lymph nodes after treatment of PMA and ionomycin (3 h). The results are representatives of three separate experiments. Signiﬁcance was
determined by Student’s t test (*, P < 0:05). iLN: inguinal lymph nodes.
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Fig. 9. Combination of PG-based chemotherapy and tumor lysate-
pulsed DC (TP-DC) completely inhibits the growth of MCA-102 cells.
C57BL/6 mice were immunized once subcutaneously with 1 106 DC
of TP-DC or unpulsed DC (Normal-DC). One week later, 1 106
MCA-102 tumor cells were intradermally inoculated into the left ﬂank.
The size of the growing MCA-102 tumor cells was measured every
7 days using microcalipers. Each group consisted of ﬁve mice (n ¼ 5).
The signiﬁcance was determined by Student’s t test (*, P < 0:05).
G.-Y. Kim et al. / FEBS Letters 576 (2004) 391–400 399responses plays a critical role in protecting against various
types of tumors [34]. The administration in vivo of re-
combinant IL-12 induced a profound but transient commit-
ment to Th-1-associated patterns of cytokine and antibody
production [35]. The repeated injection of recombinant IL-12
at relatively high doses showed severe toxicities, including an
increase in transaminase concentration, pulmonary toxicity,
and leukopenia [36]. Therefore, it might be better to use acti-
vated and mature DC in clinical applications. Based on the
results of this study, which found that the administration of
PG in vivo stimulates the production of IL-12 and the ex-
pression of surface molecules on DC, PG can augment thematuration of DC. This suggests that PG could be used as a
novel stimulatory adjuvant of DC in vivo, instead of, or in
addition to, TNF-a, CD40 ligand, or LPS.
In summary, this study found that the administration of PG
induced anti-tumor and immunomodulating activities via
maturation of CD11cþCD8þ DC in tumor-bearing mice. The
inhibitory eﬀect of PG on the growth of MCA-102 tumor cells
is associated with its immunoregulatory properties, including
the induction of IL-12 and IFN-c production leading to a Th-1
dominant state. These eﬀects were made more pronounced by
the substantial expression of surface molecules. Therefore, PG
would be useful in preventing tumor growth, and it also has
the advantage of having no side eﬀects. Attempts to clarify the
mechanism responsible for inhibitory eﬀects of PG on tumor
growth are now under study.
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